0001100397
false
0001100397
2023-09-15
2023-09-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 15, 2023
AYALA
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36138 |
|
02-0563870 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
9
Deer Park Drive, Suite K-1
Monmouth
Junction, NJ |
|
08852 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (609) 452-9813
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On
September 15, 2023, Ayala Pharmaceuticals, Inc. (the “Company”) entered into a Side Letter Agreement for Conversion (the
“Side Letter Agreement”) with Israel Biotech Fund I, L.P., Israel Biotech Fund II, L.P. and certain other investors named
therein (the “Investors”). The Side Letter Agreement references (i) the merger contemplated by the Agreement and Plan of
Merger and Reorganization, dated as of July 26, 2023, between the Company, Biosight Ltd. (“Biosight”) and a wholly owned
subsidiary of the Company (the “Merger Agreement”), pursuant to which such subsidiary shall merge with and into Biosight,
with Biosight surviving as a wholly owned subsidiary of the Company (the “Merger”), (ii) that certain Senior Secured Convertible
Promissory Note entered into between the Company and the investors named therein for an original principal amount of up to $2,000,000
(the “Promissory Note”), which was previously disclosed by the Company in its Quarterly Report on Form 10-Q for the quarter
ended June 30, 2023, and (iii) a Simple Agreement for Future Equity by and between Biosight and the Investors, pursuant to which the
Investors agreed to invest in Biosight up to $2,500,000, and Biosight agreed to issue equity interests in Biosight to the Investors in
certain circumstances (the “SAFE”).
Pursuant
to the Side Letter Agreement, the Company and the Investors agreed that should the Merger be consummated prior to the termination of
the SAFE, then the Investors shall be entitled to receive, in consideration for amounts actually invested in Biosight up to $2,500,000,
shares of the common stock, par value $0.001 per share, of the Company (the “Ayala Common Stock”). The number of shares to
be so issued would be equal to the amounts actually invested by the Investors in Biosight, divided by a conversion price equal to sixty-five
percent (65%) of either (a) if definitive agreements with respect to private investments in public equity transactions involving shares
of the Ayala Common Stock (“PIPE Transaction”) are executed prior to the consummation of the Merger and the PIPE Transaction
is consummated substantially simultaneous with the closing of the Merger, the lowest effective price per share at which shares of Ayala
Common Stock are purchased in the PIPE Transaction, or (b) if the conditions set forth in clause (a) are not satisfied, the average of
the closing prices of the Ayala Common Stock on the OTCQB on the five trading days immediately preceding the date on which the closing
of the Merger occurs. The Side Letter Agreement also provides that (i) should the Merger be closed prior to the termination of the SAFE,
then, following the closing of the Merger, if the Company enters into definitive agreements for the PIPE Transaction, the Investors shall
have the right (but not the obligation) to purchase, on the same terms of the PIPE Transaction, a number of shares of Ayala Common Stock
equal to up to all of the portion, if any, of the $2,500,000 that they were entitled to invest under the SAFE that was never actually
invested by the Investors (the “Uninvested Amount”), except that the price per share shall be equal to sixty-five percent
(65%) of the lowest effective price per share at which shares of Ayala Common Stock are purchased in the PIPE Transaction, and (ii) if
the PIPE Transaction is not consummated by the date that is six months following the closing of the Merger, then, for a period of 30
days following such date, the Investors shall have the right (but not the obligation) to purchase a number of shares of Ayala Common
Stock equal to up to all of the Uninvested Amount at a price per share equal to sixty-five percent (65%) of the average of the closing
prices of the Ayala Common Stock on the OTCQB on the five trading days immediately preceding the date on which notice of such purchase
is delivered to the Company. The mechanics of conversion, including timing of delivery of the shares of Ayala Common Stock, under the
Side Letter Agreement shall be substantially the same as the mechanics of conversion, including timing of delivery of the shares of Ayala
Common Stock pursuant to the Promissory Note
The
Side Letter Agreement, and the shares of Ayala Common Stock issuable pursuant thereto, are being offered and sold pursuant to the exemption
from the registration requirements of the Securities Act of 1933, as amended, afforded by Section 4(a)(2) thereof, for the sale of securities
not involving a public offering.
Item
3.02 Unregistered Sales of Equity Securities.
The
information included in Item 1.01 of Current Report is also incorporated by reference into this Item 3.02 of this Current Report to the
extent required.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| September
21, 2023 |
AYALA
PHARMACEUTICALS, INC. |
| |
|
|
| |
By: |
/s/
Kenneth A. Berlin |
| |
Name: |
Kenneth A. Berlin |
| |
Title: |
President and Chief Executive Officer |
Exhibit
10.1
SIDE
LETTER AGREEMENT FOR CONVERSION
September
11, 2023
Reference
in this Side Letter Agreement for Conversion (this “Agreement”) is made to the Simple Agreement for Future Equity
by and between Biosight Ltd., an Israeli company (“Biosight”), and the Investors named on the signature page hereto
(collectively, the “Investors”), dated as of the date hereof (the “Biosight SAFE”). Capitalized
terms used, but not defined, in this Agreement shall have the meanings ascribed to them in the Biosight SAFE.
WHEREAS,
(i) prior to the execution of this Agreement, Ayala Pharmaceuticals, Inc. (“Ayala”) and Biosight have, together
with a wholly owned subsidiary of Ayala, entered into an Agreement and Plan of Merger and Reorganization between the Biosight, Ayala
and such subsidiary, dated as of July 26, 2023 (the “Merger Agreement”), pursuant to which the parties thereto agreed
to consummate the Merger with Ayala and (ii) Ayala and one of the Investors entered into a Senior Secured Convertible Promissory Note,
dated as of even date hereof (the “Promissory Note”).
WHEREAS,
Ayala and the Investors wish to agree that, should the Merger with Ayala be closed prior to the termination of the Biosight SAFE,
then the Investors shall be entitled to receive, in consideration for the Initial Amount and the Additional Amount, shares of the common
stock of Ayala, par value $0.001 per share (the “Ayala Common Stock”), on the terms and conditions set forth herein.
NOW
THEREFORE, for good and valuable consideration, and intending to be legally bound hereby, the parties hereto agree as follows:
1.
Should the Merger with Ayala be closed prior to the termination of the Biosight SAFE, then, immediately prior to the closing of the Merger
with Ayala, Ayala shall issue to the Investors a number of shares of Ayala Common Stock (the “Initial Amount Shares”)
equal to:
(x)
the sum of (A) the Initial Amount and (B) any portion of the Additional Amount actually invested by Investors in Biosight prior to the
Merger, divided by
(y)
a price per share equal to sixty-five percent (65%) of either:
(i)
if definitive agreements with respect to an Ayala PIPE (as defined below) are executed prior to the Merger with Ayala and the Ayala PIPE
is consummated substantially simultaneous with the closing of the Merger with Ayala, the lowest effective price per share at which shares
of Ayala Common Stock are purchased in such Ayala PIPE, or
(ii)
if the conditions set forth in clause (y)(i) are not satisfied, the average of the closing prices of the Ayala Common Stock on the OTCQB
on the five trading days immediately preceding the date on which the closing of the Merger with Ayala occurs.
2.
Should the Merger with Ayala be closed prior to the termination of the Biosight SAFE, then, following the Closing of the Merger with
Ayala, if Ayala enters into definitive agreements for a private investment in public equity (PIPE) transaction involving the issuance
of shares of Ayala Common Stock (or securities convertible into such shares) (the “Ayala PIPE”), the Investors shall
have the right (but not the obligation) to invest up to all of the portion, if any, of the Additional Amount that was never actually
invested by Investors in Biosight prior to the Merger (such portion, the “Uninvested Amount”) directly in Ayala and
purchase shares of Ayala Common Stock on the same terms of the Ayala PIPE, except that the price per share shall equal to sixty-five
percent (65%) of the lowest effective price per share at which shares of Ayala Common Stock are purchased in the Ayala PIPE (the shares
of Ayala Common Stock issuable to the Investors in such event, the “Additional Amount PIPE Shares”). Ayala shall inform
the Investors about the Ayala PIPE no later than 10 days prior to the date on which it executes the definitive agreements therefor and
the Investors shall have up to 10 days following the date of such notice to exercise their aforesaid right by way of written notice to
Ayala.
3.
If the Ayala PIPE is not consummated within six (6) months following the closing of the Merger with Ayala (such date, the “Trigger
Date”), then, for a period of 30 days following the Trigger Date, the Investors shall have the right (but not the obligation)
to invest up to all of the Univested Amount directly in Ayala (by way of delivering a written notice to Ayala) and purchase shares of
Ayala Common Stock at a price per share equal to sixty-five percent (65%) of the average of the closing prices of the Ayala Common Stock
on the OTCQB on the five trading days immediately preceding the date on which such notice is delivered to Ayala (the shares of Ayala
Common Stock issuable to the Investors in such event, the “Additional Amount No PIPE Shares”and together with the
Initial Amount Shares and the Additional Amount PIPE Shares, the “Conversion Shares”).
4.
The mechanics of conversion, including timing of delivery of the Conversion Shares, under paragraph 1, 2 and 3 hereof shall be substantially
the same as the mechanics of conversion, including timing of delivery of the Conversion Shares, in the Promissory Note (including consequences
of failure or delay in delivery). Without derogating from the generality of the foregoing, it is hereby clarified that (i) the representations
and warranties made by Ayala in the Promissory Note shall apply, mutatis mutandis, to the conversion and issuance of the Conversion Shares
and (ii) if the Conversion Shares are issued pursuant to paragraph 1 or 2 hereof in connection with the Ayala PIPE (whether as a voluntary
investment or not), then, if the Ayala PIPE entails the issuance of warrants (or similar instruments) to the investors in the PIPE, the
Investors shall be entitled to receive, along with their Conversion Shares, warrants on the same terms issuable in the Ayala PIPE (with
the number of warrants to be issued to the Investors being calculated based on the Initial Amount and the Additional Amount actually
invested by Investors in Biosight or Ayala pursuant to Biosight SAFE and/or paragraph 1 or 2 hereof, assuming, for the purpose of calculating
the number of warrants to be issued, that the percentage “sixty-five percent (65%)”in paragraphs 1 and 2 hereof were replaced
by “one hundred percent (100%)”).
5.
Two duplicate originals of this Agreement may be executed by the undersigned, each of which shall be an original, but all of which together
shall constitute one and the same instrument. Facsimile and electronic format copies of this Agreement shall have the same force and
effect as an original.
6.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof.
Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated
by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees
or agents) shall be commenced in the state and federal courts sitting in New York, New York (the “New York Courts”). Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of this Agreement), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding.
Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in
any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
7.
Any provision of this Agreement may be amended by a written instrument executed by Ayala and the Investors, acting by a Majority-in-Interest,
which amendment shall be binding on all successors and assigns. Any provision of this Agreement may be waived by the party seeking enforcement
thereof, which waiver shall be binding on all successors and assigns. Any waiver by Ayala or the Investors must be in writing. Any waiver
by Ayala or the Investors of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other
breach of such provision or of any breach of any other provision of this Agreement. The failure of Ayla or the Investors to insist upon
strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the
right thereafter to insist upon strict adherence to that term or any other term of this Agreement on any other occasion.
8.
If any provision of this Agreement is invalid, illegal or unenforceable, the balance of this Agreement shall remain in effect, and if
any provision is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances.
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]
IN
WITNESS WHEREOF, the undersigned have executed this Letter of Instructions in connection with the Biosight SAFE.
| |
COMPANY: |
| |
|
|
| |
Ayala
Pharmaceuticals, Inc. |
| |
|
|
| |
Signature: |
/s/
Kenneth A. Berlin |
| |
Name: |
Kenneth
A. Berlin |
| |
Title: |
President
& CEO |
| |
Address: |
9
Deer Park Drive, Suite K-1 |
| |
|
Monmouth
Junction, NJ USA 08852 |
| |
Email: |
ken.b@ayalapharma.com
|
[Signature
Page for Ayala Letter of Instructions- IBF]
| |
INVESTORS: |
| |
|
| |
Israel
Biotech Fund I, L.P. |
| |
By
its general partner: |
| |
Israel
Biotech Fund GP Partners, L.P. |
| |
By
its general partner: |
| |
I.B.F.
Management, Ltd. |
| |
|
| |
Signature: |
/s/
Ido Zairi |
| |
Name: |
Ido
Zairi |
| |
Title: |
Director
|
| |
Israel
Biotech Fund II, L.P. |
| |
By
its general partner: |
| |
Israel
Biotech Fund GP Partners II, L.P. |
| |
By
its general partner: |
| |
I.B.F.
Management, Ltd. |
| |
|
|
| |
Signature: |
/s/
Ido Zairi |
| |
Name: |
Ido
Zairi |
| |
Title: |
Director
|
| |
|
|
[Signature
Page for Ayala Letter of Instructions- Arkin]
| |
INVESTORS: |
| |
|
| |
Arkin
Bio Ventures L.P. |
| |
By
its general partner: |
| |
Arkin
Bio Ventures Partners Ltd. |
| |
|
| |
Signature: |
/s/
Moshe Arkin |
| |
Name: |
Moshe
Arkin |
| |
Title: |
Director
|
| |
Arkin
Communication Ltd. |
| |
|
| |
Signature: |
/s/
Moshe Arkin |
| |
Name: |
Moshe
Arkin |
| |
Title: |
Director
|
[Signature
Page for Ayala Letter of Instructions- Marstrand Partners L.P.]
| |
INVESTORS: |
| |
|
| |
Marstrand
Partners L.P. |
| |
By
its general partner: |
| |
|
| |
Signature: |
/s/
Aaron Sasson |
| |
Name: |
Aaron
Sasson |
| |
Title: |
Partner
|
| |
|
|
[Signature
Page for Ayala Letter of Instructions- Odesey I, L.P.]
| |
INVESTORS: |
| |
|
| |
Odesy
I, L.P. |
| |
|
| |
Signature: |
/s/
Ori Sasson |
| |
Name: |
Ori
Sasson |
| |
Title: |
Founder
|
[Signature
Page for Ayala Letter of Instructions- Biotel Limited]
| |
INVESTORS: |
| |
|
|
| |
Biotel
Limited |
| |
|
|
| |
Signature: |
/s/
Rodney Hodges |
| |
Name: |
Rodney
Hodges |
| |
Title: |
duly
authorized by Champel Directors |
| |
Limited
to sign on its behalf as corporate |
| |
director
of Biotel Limited |
[Signature
Page for Ayala Letter of Instructions- Do-Tsach Ltd.]
| |
INVESTORS: |
| |
|
|
| |
Do-Tsach,
Ltd. |
| |
|
|
| |
Signature: |
/s/
Tzachy Sultan |
| |
Name: |
Tzachy
Sultan |
| |
Title: |
Director
|
[Signature
Page for Ayala Letter of Instructions- Sharam I. Sasson and Fariba J. Sasson, Trustees of the Sasson Family Trust U/D/T dated December
28, 1994]
| |
INVESTORS: |
| |
|
| |
Sharam
I. Sasson and Fariba J. Sasson, |
| |
Trustees
of the Sasson Family Trust |
| |
U/D/T
dated December 28, 1994. |
| |
|
| |
Signature: |
/s/
Sharam I. Sasson and Fariba J. |
| |
|
Sasson,
Trustees |
| |
Name: |
Sharam
I. Sasson and Fariba J. |
| |
|
Sasson,
Trustees |
| |
Title: |
Trustee
|
v3.23.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
